Inify Laboratories - notice of Extraordinary General Meeting on December 4, 2025
Inify Laboratories - notice of Extraordinary General Meeting on December 4, 2025
Stockholm - November 12, 2025 - Inify Laboratories AB (publ), a unique
laboratory service that provides cancer diagnostics within pathology, hereby
invites its shareholders to Extraordinary General Meeting on December 4, 2025.
Please find attached the invitation including attachment, agenda and details on
how to register and vote. The invitation is also available on the company's
website: www.inify.com (https://inify-my.sharepoint.com/personal/ann
-charlotte_linderoth_inify_com/Documents/INIFY%20Laboratories%20AB/IR%20och%20reg
ulatoriskt/Bolagsstämma/Extra%20bolagsstämma%202024-12
-06/Kallelse%20och%20bilagor/www.inify.com).
For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann
[email protected] or: [email protected].
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Stockholm, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.